A Phase II Study of Oral ENMD-2076 Administered to Patients With Advanced/Metastatic Soft Tissue Sarcoma
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2017
Price : $35 *
At a glance
- Drugs ENMD 2076 (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 07 Sep 2017 According to a CASI Pharmaceuticals media release, The correlative genomics testing has been completed and a publication is expected to be submitted in 2017.
- 14 Mar 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 05 Nov 2015 Results published in a CASI Pharmaceuticals media release.